ISRCTN68610794 https://doi.org/10.1186/ISRCTN68610794

Phase I trial: Celerion code CA33748

Submission date 07/01/2025	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 13/01/2025	**Overall study status** Deferred	[ ] Statistical analysis plan [ ] Results
Last Edited 13/01/2025	**Condition category** Other	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Dr Nadine Abdullah

ORCID ID
https://orcid.org/0000-0001-7772-7724

Contact details
22-24 Lisburn Road
Belfast
United Kingdom
BT9 6AD
+44289055 4000
nadine.abdullah@celerion.com

Type(s)
Scientific

Contact name
Dr Akhilesh Shama

Contact details
Alkem House, Devashish, Adjacent to Matulya Centre, Senapati Bapat, Marg, Lower Parel
Mumbai
India

400 013
+9122 39829999
akhilesh.sharma@alkem.com

Type(s)
Public

Contact name
Dr Vinayaka Shahavi

Contact details
Alkem House, Devashish, Adjacent to Matulya Centre, Senapati Bapat, Marg, Lower Parel
Mumbai
India
400 013
+9122 39829999
vinayaka.shahavi@alkem.com

Additional identifiers

Clinical Trials Information System (CTIS)
2021-004177-32

Integrated Research Application System (IRAS)
1004078

Protocol serial number
Celerion code: CA33748

Study information

Scientific Title
Phase I trial: Celerion code CA33748

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 14/12/2021, London - Harrow Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, United Kingdom; +44 (0)207 104 8137; harrow.rec@hra.nhs.uk), ref: 21/LO/0838

Primary study design
Interventional

Study design
Pharmacokinetic pharmacodynamic safety and tolerability study in 189 healthy adult volunteers

Study type(s)
Safety, Efficacy

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
22/05/2024

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Sex
Male

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
10/01/2022

Date of final enrolment
30/08/2023

Locations

Countries of recruitment
United Kingdom

England

Northern Ireland

Bulgaria

Poland

Study participating centre
Celerion GB Limited
Suite 1, 7th Floor 50 Broadway
London
United Kingdom
SW1H 0BL

Study participating centre
MTZ Clinical Research powered by Pratia
Pratia S.A., Gladka 22
Warszawa
Poland
02-172

Study participating centre
COMAC
3 Sv. Georgi Sofiyski str./13 Urvich str.
Sofia
Bulgaria
1606/1612

Sponsor information

Organisation
Alkem (India)

ROR
https://ror.org/04kwy9224

Organisation
Enzene BioSciences Ltd.

Funder(s)

Funder type
Industry

Funder Name
Alkem Laboratories Ltd.

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are not expected to be made available due to the protection of commercially confidential information.

IPD sharing plan summary
Not expected to be made available